Techedge Board Has Approved for Its New Name as China Biopharma Inc.
ISELIN, N.J. -- Techedge Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :TEDG) announced that its board of directors has unanimously approved to change its name to the new name as China Biopharma Inc.
"We have finally transitioned our old business operation to the biopharmaceutical business operation in China. It is a right time to change our name. This proposed new name would be more accurately reflect our current business operation as we are a leading developer, producer and distributor of vaccine products in China. We are ready to distribute flu vaccines as the flu season in China is fast approaching" Peter Wang, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Techedge Inc. stated.
About Techedge, Inc.
Techedge, Inc. is a fast growing developer, producer, and distributor of biopharmaceutical products in China. It has wholly owned subsidiary Wholly Owned Subsidiary
A subsidiary whose parent company owns 100% of its common stock.
In other words, the parent company owns the company outright and there are no minority owners. , China Biopharma Limited and owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd ("ZTB"). The Company's current products consist of human vaccines against influenza, epidemic hemorrhagic fever epidemic hemorrhagic fever
An acute viral hemorrhagic fever characterized by headache, high fever, sweating, thirst, photophobia, coryza, cough, myalgia, arthralgia, and abdominal pain with nausea and vomiting. (HFV HFV High-frequency ventilation ), and Japanese Encephalitis Japanese Encephalitis Definition
Japanese encephalitis is an infection of the brain caused by a virus. The virus is transmitted to humans by mosquitoes. (JEV JEV Jesuit European Volunteers
JEV Joinville Eau Vive (France) ) with high reputation and market shares among Chinese made vaccines. Through its investment and ownership of leading Chinese biopharmaceutical companies, the company plans to build the most efficient and most profitable biopharmaceutical company in China by introducing the most advanced technology, best product, and experienced management team. With a fast growing market, newly completed production facility, and several other new vaccines in the pipeline, it is expected to have a steady business growth.
FORWARD-LOOKING STATEMENT DISCLAIMER
Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
For more information, please visit its website at www.techedgeinc.net